Long-term Cardiovascular Safety of Ustekinumab in Psoriasis and Psoriatic Arthritis: Results from an Observational Post-Authorization Safety Study Based on Swedish National Registers

Psoriatic Arthritis

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Res Ther

Gladman DD, Nash P, Mease PJ, FitzGerald O, Duench S, Cadatal MJ, Masri KR

doi: 10.1186/s13075-024-03442-2

Further Publications Immunology

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

J Autoimmun

Bustaffa M, Bella S, Bayindir Y, Amaryan G, Gallizzi R, Papadopoulou-Alataki E, Fabio G, Assalia N, Amarilyo G, Bakkaloglu S, Jesenak M, Breda L, Anton J, Legger E, Alessio M, Simonini G, Rigante D, Obici L, Kuemmerle-Deschner J, Kasapcopur O, Insalaco A, Glerup M, Frenkel J, Brunner J, Horneff G, Sánchez-Manubens J, Cantarini L, Spagnolo A, Alataki S, Carrabba M, Belder N, Porreca A, Caorsi R, Ruperto N, Gattorno M, Ozen S, Eurofever Registry

doi: 10.1016/j.jaut.2025.103421

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Further Publications Rheumatology

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

BMJ Open

Weinblatt ME, Taylor PC, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Curtis P, Gupta A, Nijhawan R, O'Shea C, Rayner K, Saurigny D, Shelton C, Wang M, Wang R, Fleischmann RM

doi: 10.1136/bmjopen-2024-088869

Further Publications Dermatology

Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the Phase III EASE Study

Br J Dermatol

Murrell DF, Bodemer C, Bruckner AL, Cunningham T, Davis C, Fernández MF, Kiritsi D, Maher L, Sprecher E, Torres Pradilla M, Kern JS

doi: 10.1093/bjd/ljaf022

Psoriasis

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

J Eur Acad Dermatol Venereol

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, Papp KA, Colombo MJ, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B

doi: 10.1111/jdv.20553

Further Publications Rheumatology

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology (Oxford)

Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Vaux T, Prajapati C, Manente M, Marten A, Gensler LS

doi: 10.1093/rheumatology/keaf009

Psoriasis

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Zebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2024.10.104

Psoriatic Arthritis

Clinical Significance of Gut Microbiota Community Types for Long-term Response to Fecal Microbiota Transplantation in Patients with Psoriatic Arthritis

Arthritis Rheumatol

Qin P, Kragsnaes MS, Holm DK, Horn HC, Nilsson AC, Kjeldsen J, Kristiansen K, Ellingsen T

doi: 10.1002/art.43359

Related content

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the Phase III EASE Study

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

Clinical Significance of Gut Microbiota Community Types for Long-term Response to Fecal Microbiota Transplantation in Patients with Psoriatic Arthritis